
COGT Stock Forecast & Price Target
COGT Analyst Ratings
Bulls say
Cogent Biosciences is poised for significant advancement in 2025, positioning itself as a potential target for mergers and acquisitions due to its strategic developments in precision therapies. The company’s investigational drug, bezuclastinib, has demonstrated promising data from the APEX, PEAK, and SUMMIT trials, indicating its potential as a competitive treatment option across various malignancies. Such positive clinical outcomes, in conjunction with anticipated growth, enhance Cogent's attractiveness to investors and the broader market.
Bears say
Cogent Biosciences Inc. is projected to experience a significant net loss of $2.28 per share for the full year 2025, indicating ongoing financial challenges. Key risks affecting the company's outlook include potential negative clinical data, slower than anticipated development timelines, setbacks in later-stage trials, and difficulties in obtaining regulatory approvals for its therapies. Additionally, lower-than-expected commercial success and long-term dilution risk further contribute to the negative sentiment surrounding the company’s financial prospects.
This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.
COGT Analyst Forecast & Price Prediction
Start investing in COGT
Order type
Buy in
Order amount
Est. shares
0 shares